Ribomic (4591) Stock Overview

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. It develops drugs in the areas of pain, heart failure, achondroplasia, osteoarthritis, diabetic retinopathy, pulmonary arterial hypertension, osteosclerosis, and fibrosis, as well as age-related macular degeneration. Ribomic Inc. has a joint research and development agreement with ASKA Pharmaceutical Co., Ltd. for drug discovery research and development targeting specific hormone receptors. The company was incorporated in 2003 and is headquartered in Tokyo, Japan.